Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL20704647 | 0.98 | PABPC1 (0.70) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Bromide SCHEMBL3616347 | 0.98 | KDM4E (0.70) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL5907533 | 0.98 | ALDH1A1 (0.72) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL8660257 | 0.93 | KDM4E (0.64) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL8660261 | 0.91 | ALDH1A1 (0.59) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL8968159 | 0.89 | KDM4E (0.63) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL765905 | 0.84 | KDM4E (0.76) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| SCHEMBL26707030 | 0.84 | ALDH1A1 (0.63) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Bromide SCHEMBL31501128 | 0.84 | LMNA (0.74) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E | |
| Ammonia Solution, Strong SCHEMBL28760030 | 0.82 | KDM4E (0.73) | ALDH1A1LMNAHTTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355645-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON INC (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040097495-A1 | Method for treating fibrotic diseases or other indications IIIC | WAGLE DILIP (US) | 2004-05-20 | — | — | US | claimed |
| EP-1355645-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | Alteon, Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| US-20020183365-A1 | Method for treating fibrotic diseases or other indications IIIC | ALTEON, INC. | 2002-12-05 | — | — | US | claimed |
| WO-2002067851-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| US-11826426-B2 | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | THE UNIVERSITY OF CHICAGO (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826426-B2 | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | THE UNIVERSITY OF CHICAGO (US) | 2023-11-28 | — | — | US | disclosed |
| CN-111194232-B | Nanoscale metal-organic layer and metal-organic nanosheet | 芝加哥大学 | 2023-01-31 | — | — | CN | disclosed |
| US-20200254095-A1 | NANOSCALE METAL-ORGANIC LAYERS AND METAL-ORGANIC NANOPLATES FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | THE UNIVERSITY OF CHICAGO | 2020-08-13 | — | — | US | disclosed |
| US-20200254095-A1 | NANOSCALE METAL-ORGANIC LAYERS AND METAL-ORGANIC NANOPLATES FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | THE UNIVERSITY OF CHICAGO | 2020-08-13 | — | — | US | disclosed |
| CN-111194232-A | Nanoscale metal-organic layers and metal-organic nanoplatelets for X-ray induced photodynamic therapy, radiotherapy, photodynamic therapy, chemotherapy, immunotherapy and any combination thereof | 芝加哥大学 | 2020-05-22 | — | — | CN | disclosed |
| EP-3638367-A1 | NANOSCALE METAL-ORGANIC LAYERS AND METAL-ORGANIC NANOPLATES FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | The University of Chicago (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-1355645-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040097495-A1 | Method for treating fibrotic diseases or other indications IIIC | WAGLE DILIP (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1359918-A1 | METHOD FOR TREATING GLAUCOMA IIIB | Alteon, Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1355645-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | Alteon, Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020183365-A1 | Method for treating fibrotic diseases or other indications IIIC | ALTEON, INC. | 2002-12-05 | — | — | US | disclosed |
| US-20020156080-A1 | Method for treating glaucoma IIIB | ALTEON, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002067851-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002053162-A1 | METHOD FOR TREATING GLAUCOMA IIIB | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097495-A1 | Method for treating fibrotic diseases or other indications IIIC | COL1A1, COL2A1, MMP1 | ALDH1A1 844/4885LMNA 208/4885HTT 1115/4885 |
| US-20020156080-A1 | Method for treating glaucoma IIIB | RHOA, GSR, PTGIR | ALDH1A1 732/4885LMNA 1155/4885HTT 1158/4885 |
| US-11826426-B2 | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | CD274, PDCD1LG2, PDCD1 | ALDH1A1 3336/4885LMNA 4088/4885HTT 3488/4885 |
| US-20200254095-A1 | NANOSCALE METAL-ORGANIC LAYERS AND METAL-ORGANIC NANOPLATES FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF | CD274, PDCD1LG2, PDCD1 | ALDH1A1 3336/4885LMNA 4088/4885HTT 3488/4885 |
| US-20020183365-A1 | Method for treating fibrotic diseases or other indications IIIC | EPX, COL2A1, COL1A1 | ALDH1A1 600/4885LMNA 1446/4885HTT 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.